Abcam, ab316325, Anti-SCN11A antibody [EPR28603-66] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal SCNBA antibody. Carrier free. Suitable for WB, IHC-Fr and reacts with Transfected cell lysate - Human, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28603-66,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:IHC-Fr, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab316325 is the carrirer-free version of
ab316324
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SCN11A also known as Nav1.9 is a voltage-gated sodium channel expressed in peripheral sensory neurons particularly in the dorsal root ganglion and trigeminal ganglion. The protein has an approximate mass of 207 kDa. SCN11A plays an important role in generating and propagating action potentials by allowing sodium ions to enter the cell. This ion influx is important for neuronal excitability and pain signal transmission. Expression of SCN11A is known to be increased in response to certain inflammatory processes and may contribute to pain perception.
Biological function summary
SCN11A contributes to the modulation of neuronal excitability and pain pathways. The channel participates in adjusting the resting membrane potential and firing threshold of neurons. It is hypothesized to function independently rather than as part of a larger protein complex. SCN11A influences the intensity and duration of pain signals affecting the perception of both acute and chronic pain. Its regulation is essential for proper sensory neuron functioning.
Pathways
SCN11A is involved in the nociceptive pain pathway which is responsible for the sensation of pain due to tissue injury. It interacts with other sodium channels such as Nav1.8 to fine-tune pain signaling under various physiological and pathological conditions. Additionally SCN11A is linked to the inflammatory response pathway where its expression can be modulated by pro-inflammatory cytokines. This interaction underlines the channel’s role in mediating neuropathic and inflammatory pain.
SCN11A is associated with neuropathic pain and familial episodic pain syndrome. Mutations in SCN11A can lead to altered channel function resulting in enhanced pain sensitivity or spontaneous pain episodes. The channel's dysfunction is also observed in conditions involving Nav1.7 another sodium channel implicated in pain disorders. Understanding the role of SCN11A in these conditions can provide insights into therapeutic targets for pain management and relief.